Insurance and altruism values of a novel treatment for hypophosphatasia: a stated preference survey in the United States.

Authors

Andrew Messali, Kyi-Sin Than, Kathryn Spurrier, Craig Wakeford, Jason Shafrin

Published in

Journal of medical economics. Volume 29. Issue 1. Pages 2539-2551. Epub Oct 15, 2026.

Abstract

To estimate the insurance and altruism values of a novel hypothetical treatment on survival gains for perinatal-/infantile-onset hypophosphatasia (HPP), a rare, severe, inherited disease, which-if untreated-leads to early mortality in children.
Residents of the United States aged 21-54 years from the general population participated in a web-based, cross-sectional, prospective, stated preference survey. The insurance value module included respondents planning to have children, whereas the altruism value module included respondents not planning to have children in the future. A multiple random staircase survey design was utilized to assess respondents' willingness to pay (WTP) for insurance coverage of the novel HPP treatment offering survival gains.
Among the 511 eligible respondents, 50.3% (n = 257) and 49.7% (n = 254) were included in the insurance value and altruism value modules, respectively. Overall, 72.2% of the respondents were aged 30-49 years (insurance module: 72.4% and altruism module: 72.0%) and 52.8% were men (insurance module: 56.8% and altruism module: 48.8%). For generous coverage of the novel HPP treatment, the mean WTP was $10.35/month or $124.22/year as additional health insurance premiums for the insurance value module (insurance value makes 90.1% of the total treatment value). The mean WTP was $9.40/month or $112.85/year as taxes for the altruism value module.
The high insurance and altruism values for the novel HPP treatment, which can significantly improve survival, suggest that health gains for children may be valued more highly than similar health gains for adults, especially in a rare disease context.

PMID:
42878124
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.